{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:43:31Z","timestamp":1790981011597,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T00:00:00Z","timestamp":1425081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40265-015-0360-7","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T09:10:31Z","timestamp":1425028231000},"page":"427-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout"],"prefix":"10.1007","volume":"75","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"key":"360_CR1","doi-asserted-by":"crossref","unstructured":"Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013. doi: 10.1136\/bmj.f5648 .","DOI":"10.1136\/bmj.f5648"},{"key":"360_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","volume":"75","author":"A Wertheimer","year":"2013","unstructured":"Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res. 2013;75:1\u20134.","journal-title":"Curr Ther Res."},{"issue":"13","key":"360_CR3","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2165\/00003495-200868130-00006","volume":"68","author":"PI Hair","year":"2008","unstructured":"Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs. 2008;68(13):1865\u201374.","journal-title":"Drugs."},{"issue":"6 Suppl","key":"360_CR4","first-page":"S1","volume":"59","author":"MA Becker","year":"2010","unstructured":"Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(6 Suppl):S1\u20138.","journal-title":"J Fam Pract."},{"issue":"2","key":"360_CR5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clinthera.2012.12.011","volume":"35","author":"P Ye","year":"2013","unstructured":"Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180\u20139.","journal-title":"Clin Ther."},{"issue":"5","key":"360_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/17425255.2014.904285","volume":"10","author":"HK Grewal","year":"2014","unstructured":"Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol. 2014;10(5):747\u201358.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"360_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","volume":"10","author":"F Rees","year":"2014","unstructured":"Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271\u201383.","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"360_CR8","first-page":"22","volume":"38","author":"M Cassagnol","year":"2013","unstructured":"Cassagnol M, Saad M. Pharmacologic management of gout. US Pharm. 2013;38(3):22\u20136.","journal-title":"US Pharm."},{"issue":"8","key":"360_CR9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/14656560902950742","volume":"10","author":"N Schlesinger","year":"2009","unstructured":"Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout\u2014what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319\u201328.","journal-title":"Expert Opin Pharmacother."},{"issue":"2","key":"360_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.rdc.2014.01.013","volume":"40","author":"NL Edwards","year":"2014","unstructured":"Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014;40(2):375\u201387.","journal-title":"Rheum Dis Clin North Am."},{"issue":"10","key":"360_CR11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"360_CR12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res."},{"issue":"6","key":"360_CR13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol."},{"key":"360_CR14","unstructured":"Menarini International Operations Luxembourg S.A. Adenuric 80\u00a0mg film-coated tablets: EU summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000777\/WC500021812.pdf . Accessed 23 Oct 2014."},{"key":"360_CR15","unstructured":"Takeda Pharmaceuticals America, Inc. ULORIC (febuxostat) tablet for oral use: US prescribing information. 2013. http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=ULORICPI&cacheRandomizer=579232da-e46d-4387-95a2-8f36cce19d42 . Accessed 28 Oct 2013."},{"key":"360_CR16","volume-title":"Feburic\u00ae: full prescribing information","author":"Teijin Pharma Limited","year":"2011","unstructured":"Teijin Pharma Limited. Feburic\u00ae: full prescribing information. Tokyo: Teijin Pharma Limited; 2011."},{"issue":"11","key":"360_CR17","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","volume":"31","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase\/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503\u201318.","journal-title":"Clin Ther."},{"issue":"6","key":"360_CR18","first-page":"1209","volume":"4","author":"M Hu","year":"2008","unstructured":"Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209\u201320.","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"360_CR19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szab\u00f3 C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87\u2013114.","journal-title":"Pharmacol Rev."},{"issue":"1","key":"360_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","volume":"12","author":"MD Mayer","year":"2005","unstructured":"Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22\u201334.","journal-title":"Am J Ther."},{"key":"360_CR21","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186\/ar2978 .","journal-title":"Arthritis Res Ther."},{"key":"360_CR22","first-page":"S498","volume":"65","author":"KG Saag","year":"2013","unstructured":"Saag KG, Becker MA, Whelton A, et al. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: a randomized controlled trial [abstract no. 1178]. Arthritis Rheum. 2013;65:S498\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"360_CR23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5414\/CP201648","volume":"50","author":"M Tsai","year":"2012","unstructured":"Tsai M, Wu J-T, Gunawardhana L, et al. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. Int J Clin Pharmacol Ther. 2012;50(5):331\u20137.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"3","key":"360_CR24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916\u201323.","journal-title":"Arthritis Rheum."},{"issue":"11","key":"360_CR25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540\u20138.","journal-title":"Arthritis Care Res."},{"issue":"23","key":"360_CR26","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med."},{"issue":"4 Suppl 2","key":"360_CR27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/RHU.0b013e31821d36de","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S19\u201326.","journal-title":"J Clin Rheumatol."},{"issue":"4 Suppl 2","key":"360_CR28","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/RHU.0b013e31821d351d","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S35\u201343.","journal-title":"J Clin Rheumatol."},{"issue":"4 Suppl 2","key":"360_CR29","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13\u20138.","journal-title":"J Clin Rheumatol."},{"issue":"6","key":"360_CR30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","volume":"17","author":"X Huang","year":"2014","unstructured":"Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679\u201386.","journal-title":"Int J Rheum Dis"},{"key":"360_CR31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188\u201394.","journal-title":"Rheumatology."},{"key":"360_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2318-12-11","volume":"12","author":"RL Jackson","year":"2012","unstructured":"Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >65\u00a0years of age. BMC Geriatr. 2012;12:11. doi: 10.1186\/1471-2318-12-11 .","journal-title":"BMC Geriatr."},{"issue":"12","key":"360_CR33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/15257770.2011.603715","volume":"30","author":"MA Becker","year":"2011","unstructured":"Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011\u20137.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"11","key":"360_CR34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/dom.12135","volume":"15","author":"MA Becker","year":"2013","unstructured":"Becker MA, MacDonald PA, Hunt BJ, et al. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049\u201355.","journal-title":"Diabetes Obes Metab."},{"key":"360_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2474-13-15","volume":"13","author":"AF Wells","year":"2012","unstructured":"Wells AF, MacDonald PA, Chefo S, et al. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012;13:15. doi: 10.1186\/1471-2474-13-15 .","journal-title":"BMC Musculoskelet Disord."},{"issue":"2","key":"360_CR36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.20680","volume":"64","author":"S Chohan","year":"2012","unstructured":"Chohan S, Becker MA, MacDonald PA, et al. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res. 2012;64(2):256\u201361.","journal-title":"Arthritis Care Res."},{"key":"360_CR37","unstructured":"European Medicines Agency. CHMP assessment report for Adenuric. International Nonproprietary Name: febuxostat. Procedure no. EMEA\/H\/C\/777. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000777\/WC500021815.pdf . Accessed 16 Oct 2014."},{"issue":"14","key":"360_CR38","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386\u201397.","journal-title":"Clin Ther."},{"key":"360_CR39","unstructured":"Takeda. Phase 3, febuxostat, allopurinol and placebo-controlled study in gout subjects. (APEX) [ClinicalTrials.gov identifier NCT00174915]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00174915 . Accessed 23 Sept 2014."},{"issue":"1","key":"360_CR40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","volume":"125","author":"A Whelton","year":"2013","unstructured":"Whelton A, MacDonald PA, Chefo S, et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106\u201314.","journal-title":"Postgrad Med."},{"issue":"1","key":"360_CR41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, MacDonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7\u201313.","journal-title":"J Clin Rheumatol."},{"issue":"4","key":"360_CR42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40292-014-0051-6","volume":"21","author":"D Grassi","year":"2014","unstructured":"Grassi D, Pontremoli R, Bocale R, et al. Therapeutic approaches to chronic hyperuricemia and gout. High Blood Press Cardiovasc Prev. 2014;21(4):243\u201350.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"Suppl 10","key":"360_CR43","first-page":"S811","volume":"64","author":"RA Overman","year":"2012","unstructured":"Overman RA, Mandell BF, Deal CL. Use of uric lowering therapies within a large health care system. [abstract no. 1909]. Arthritis Rheum. 2012;64(Suppl 10):S811.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"360_CR44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3810\/pgm.2014.03.2741","volume":"126","author":"H Hatoum","year":"2014","unstructured":"Hatoum H, Khanna D, Lin S-J, et al. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65\u201375.","journal-title":"Postgrad Med."},{"key":"360_CR45","first-page":"S771","volume":"64","author":"MA Becker","year":"2012","unstructured":"Becker MA, Ye X, Akhras KS, et al. Comparing clinical characteristics and comorbidities of gout patients treated with allopurinol or febuxostat [abstract no. 1814]. Arthritis Rheum. 2012;64:S771\u20132.","journal-title":"Arthritis Rheum"},{"key":"360_CR46","first-page":"S847","volume":"65","author":"F Perez-Ruiz","year":"2013","unstructured":"Perez-Ruiz F, Herrero-Beites AM. Liver outcomes in gout patients treated with febuxostat and altered liver function tests [abstract no. 1987]. Arthritis Rheum. 2013;65:S847.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"360_CR47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/BOR.0000000000000031","volume":"26","author":"LK Stamp","year":"2014","unstructured":"Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol. 2014;26(2):162\u20138.","journal-title":"Curr Opin Rheumatol."},{"issue":"7","key":"360_CR48","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","volume":"4","author":"TM MacDonald","year":"2014","unstructured":"MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. doi: 10.1136\/bmjopen-2014-005354 .","journal-title":"BMJ Open."},{"issue":"1","key":"360_CR49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","volume":"164","author":"WB White","year":"2012","unstructured":"White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14\u201320.","journal-title":"Am Heart J."},{"issue":"5","key":"360_CR50","first-page":"453","volume":"15","author":"SM Beard","year":"2014","unstructured":"Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15(5):453\u201363.","journal-title":"Eur J Health Econ."},{"issue":"7","key":"360_CR51","doi-asserted-by":"crossref","first-page":"A513","DOI":"10.1016\/j.jval.2012.08.1751","volume":"15","author":"M Cuesta","year":"2012","unstructured":"Cuesta M, Perez Alcantara F, Brosa M. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Spain [abstract no. PSY28]. Value Health. 2012;15(7):A513.","journal-title":"Value Health."},{"key":"360_CR52","doi-asserted-by":"crossref","unstructured":"Richette P, Doherty M, Pascual E, et al. Updated evidence-based recommendations for the management of gout [abstract no. SAT0531]. Ann Rheum Dis 2014;73(Suppl 2). doi: 10.1136\/annrheumdis-2014-eular.5022 .","DOI":"10.1136\/annrheumdis-2014-eular.5022"},{"issue":"1","key":"360_CR53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4081\/reumatismo.2013.4","volume":"65","author":"M Manara","year":"2013","unstructured":"Manara M, Bortoluzzi A, Favero M, et al. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo. 2013;65(1):4\u201321.","journal-title":"Reumatismo."},{"key":"360_CR54","unstructured":"Spanish Society of Rheumatology (SER). Clinical practice guidelines for management of gout. 2013. http:\/\/www.ser.es\/ArchivosDESCARGABLES\/Guias_Paciente\/GuipClinGot_1140226_EN.pdf . Accessed 9 Feb 2015."},{"issue":"8\u20139","key":"360_CR55","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","volume":"23","author":"MA Becker","year":"2004","unstructured":"Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids. 2004;23(8\u20139):1111\u20136.","journal-title":"Nucleos Nucleot Nucleic Acids."},{"issue":"1","key":"360_CR56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270005282634","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski B, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88\u2013102.","journal-title":"J Clin Pharmacol."},{"key":"360_CR57","unstructured":"Takeda. Efficacy and safety of oral febuxostat in participants with gout (CONFIRMS) [ClinicalTrials.gov identifier NCT00430248]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00430248 . Accessed 22 Sept 2014."},{"issue":"2","key":"360_CR58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328\u201335.","journal-title":"Ann Rheum Dis."},{"key":"360_CR59","unstructured":"National Institute for Health and Care Excellence. Febuxostat for the management of hyperuricaemia in people with gout. NICE technology appraisal guidance 164. 2008. http:\/\/www.nice.org.uk\/guidance\/ta164\/resources\/guidance-febuxostat-for-the-management-of-hyperuricaemia-in-people-with-gout-pdf . Accessed 12 Nov 2014."},{"key":"360_CR60","unstructured":"Scottish Medicines Consortium. Febuxostat 80\u00a0mg and 120\u00a0mg tablets (Adenuric\u00ae). SMC No. 637\/10. 2010. http:\/\/www.scottishmedicines.org.uk\/files\/advice\/febuxostat-Adenuric-FINAL-August-2010.pdf . Accessed 12 Nov 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0360-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0360-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0360-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:41Z","timestamp":1559490101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0360-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,28]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0360-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,28]]}}}